1stOncology™: Cancer Intelligence Service – Page 11726 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Immunovia Reports First Quarter Interim Report January – March 2020

On April 28, 2020 Immunovia reported that first quarter interim report for January – March 2020 (Press release, Immunovia, APR 28, 2020, View Source;march-2020-301048485.html [SID1234556721]). It is available on Immunovia’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"During Q1 2020, Immunovia worked hard and continued to make great strides towards IMMray PanCan-d’s launch and the sales start of the first test for early diagnosis of pancreatic cancer, in spite of the COVID-19 global pandemic.

Work on the verification study proceeded as planned and we received all the blood samples from our KOL network. In January, our commercial team prepared detailed plans for the launch and in March and April these plans were adapted significantly to accommodate the COVID-19 situation. This included making in-person activities, such as conferences and the patient organization meetings that were canceled, into digital activities, etc.

In January, Immunovia welcomed a new Senior VP Sales NA (North America), Michael Pettigrew, to the team. Michael brings with him a very successful track record in product launches and sales growth in life science, along with unique leadership qualities. He is an important addition to Immunovia.

Following the end of Q1 2020, we provided an update on the measures the company has taken and continues to take in order to support patients, employees and public health initiatives in response to the COVID-19 pandemic. We also announced other crucial preparations that Immunovia has made in response to COVID-19, such as securing inventories of critical consumables, the successful collection of samples for the verification study including the reallocation of extra blood samples to the efforts of securing all samples for the verification study. All this done to facilitate the uninterrupted continuation towards commercialization start.

We reiterate that Immunovia’s R&D laboratories and clinical laboratory in Lund, along with the production facilities are fully operational. They all have plans in place to help sustain operations in these unusual times."

– Excerpt from the CEO Mats Grahn’s comment on the report

First Quarter Interim Report for January – March 2020 Call Details:

Immunovia invites to a teleconference (in English) for investors, analysts and media on Tuesday, April 28th, 2020 at 16:30 CET.

Mats Grahn, CEO will present Immunovia and comment on the first quarter interim report for the period January – March 2020 followed by a Q&A session.

There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (View Source) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET on April 28, 2020.

ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting

On April 28, 2020 ArcherDX, Inc., UCL and the Francis Crick Institute reported new data from their research collaboration as part of the Cancer Research UK-funded UCL-sponsored TRACERx study (Press release, ArcherDX, APR 28, 2020, View Source [SID1234556720]). Based on the on-going collaboration between ArcherDX and UCL, utilizing ArcherDX’s AMPTM technology, the data demonstrated cancer circulating tumor DNA (ctDNA) monitoring for minimal residual disease (MRD) can detect relapse of non-small cell lung cancer (NSCLC) earlier than standard of care imaging surveillance in some instances. Post-operative timepoints were analyzed from 90 TRACERx patients. In patients whose cancer had relapsed and shed ctDNA, the ctDNA was detected at or before relapse with a median lead-time, or time from ctDNA detection to clinical relapse, of 164 days (range: 6 to 1,022 days) in the TRACERx study tracking a median of 200 variants per patient. Furthermore, in non-relapse patients, the assay demonstrated 99.3% clinical specificity within the research data set. Results from the analytical validation of a 50-variant version of the research assay demonstrated 100% specificity with detection down to 0.003% variant fractions at high cell-free (cfDNA) input levels.i

With more sensitive detection of ctDNA for MRD as a biomarker, it is possible for adjuvant clinical trials to be conducted in smaller and more relevant settings by only escalating therapy in patients who are set to relapse, thereby potentially reducing trial size, cost and time. The full results of the analysis will now be presented today at 2:30 p.m. ET during the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting (abstract #2025).i

"Specificity is a critical and under-appreciated requisite of frequent disease monitoring," said Christopher Abbosh, M.D., Principal Clinical Fellow, UCL. "Data from a 50-variant version of the research assay demonstrates a variant detection limit of 0.003% at high cfDNA input levels while maintaining 100% variant analytical specificity. Together, with our collaborators, we aim to establish an MRD approach to treating early-stage NSCLC in order to determine which patients are likely to relapse and overcome challenges associated with conventional adjuvant therapy trial design. We believe this approach will provide an opportunity to expand precision oncology into early-stage cancer, when the cancer is typically easier to cure."

ArcherDX’s Personalized Cancer Monitoring (PCM) development program is being developed by ArcherDX and is supported by a collaboration led by Professor Charles Swanton of UCL and the Francis Crick Institute to detect evidence of disease progression in lung cancer patients from cell-free ctDNA as part of the Cancer Research UK-funded UCL-sponsored TRACERx study. PCM applies Archer’s proprietary Anchored Multiplex PCR (AMP) technology to accurately detect exceedingly low levels of cancer-derived DNA from patient blood.

"There remains a stark unmet need to improve the current adjuvant standard of care and outcomes in patients with solid tumors," said Jason Myers, Ph.D., Chief Executive Officer and co-founder, ArcherDX. "Key to reducing patient burden in cancer treatment is a minimally invasive assay that enables tracking disease recurrence at the earliest possible time point directly at the patient’s care setting. We are thrilled to collaborate with the UCL team, which aligns closely with ArcherDX’s mission to bring the right test to the right patient at the right time."

Lung cancer is one of the most common types of cancer worldwide and a leading cause of cancer-related death.ii NSCLC is the most common type of lung canceriii and has a complex genomic landscape.iv

About TRACERx Study
TRACERx (Tracking Cancer Evolution through therapy (Rx)) lung study is the single biggest investment in lung cancer research by Cancer Research UK. Taking place over nine years, we believe the translational research programme is the first study to look at the evolution of cancer in real time and immense detail. Researchers follow patients with lung cancer all the way from diagnosis through to either disease relapse or cure after surgery, tracking and analysing how their cancer develops. TRACERx is led by UCL (University College London) via the Cancer Research UK Lung Cancer Centre of Excellence and also supported by the National Institute for Health Research, University College London Hospitals Biomedical Research Centre, Francis Crick Institute and the Rosetrees Trust.

Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR™ GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting

On April 28, 2020 Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, reported data of its first-in-human clinical trial for Universal TruUCAR GC027 in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) patients (Press release, Gracell Biotechnologies, APR 28, 2020, View Source [SID1234556719]). The data was presented in the Adoptive Cell Transfer Therapy section during the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting held on April 28.

T-ALL, a form of acute lymphoblastic leukemia, consisting of 20-25% of adult ALL, and 12-15% of pediatric ALL, represents a hard-to-treat disease with a high unmet clinical need.[1] Outcome of relapsed and refractory T-ALL remains poor, with very limited treatment options available. Most T-ALL patients relapse within two years after multi-agent chemotherapy regimens. The study of TruUCAR GC027 in relapsed and refractory T-ALL reports early efficacy outcomes of five patients treated in this area of high unmet medical need.

The clinical investigator initial trial (IIT) intends to evaluate safety and efficacy of TruUCAR GC027, the first-in-human, universal CAR-T therapy for R/R T-ALL. As of February, the study enrolled a total of five patients with R/R T-ALL, with median prior lines of therapy 5 (range 1-9). Baseline bone marrow tumor burden was 38.2% (range 4-80.2). All patients received a single infusion of TruUCAR GC027 in one of three dose levels: 0.6*10^7cells/kg, 1.0*10^7cells/kg or 1.5*10^7cells/kg. Notably, these patients were not HLA matched, and no one accepted post-infusion hematopoietic stem cell transplantation (HSCT).

Treatment efficacy was assessed in five patients with 28 days of follow-up, of which:

Five (100%) achieved a complete remission with or without complete blood count recovery (CR/CRi);
Four (80%) achieved minimum residual disease negative complete remission (MRD-CR).
All five patients tolerated the single infusion of TruUCAR GC027 with no neurotoxicity events or acute graft-versus-host disease (aGvHD) observed. Cytokine release syndrome (CRS) presented in all patients at any grade.

"We are delighted to report the outcome on the first five patients treated with TruUCAR GC027. These promising preliminary results are encouraging and warrant further evaluation of the therapy in this area of high unmet clinical need." said Dr. Martina Sersch, CMO of Gracell.

About TruUCAR

TruUCAR is Gracell’s proprietary and patented platform technology, with selected genes being edited to avoid GvHD and immune rejection without using strong immunosuppressive drugs. In addition to T-ALL antigen, the platform technology can also be implemented for other targets of hematological malignancies.

About GC027

GC027 is an investigational, off-the-shelf CAR-T cell therapy, redirected to CD7 for the treatment of T cell malignancies. GC027 was manufactured from T cells of human leukocyte antigen (HLA) unmatched healthy donors using TruUCAR technology, which is expected to improve efficacy and reduce production time, available for off-the-shelf use in a timely manner.

About T-ALL

T – Lymphoblastic Leukemia (T-ALL) is an aggressive form of acute lymphoblastic leukemia, with a diffuse invasion of bone marrow and peripheral blood. In 2015, T-ALL affected around 876,000 people globally and resulted in 110,000 deaths worldwide. T-ALL compromises about 15%-20% of all children and adult acute lymphoblastic leukemia[2]. Current standard of care therapies for T-ALL are chemotherapy and stem cell transplantation. 40-50% of patients will experience relapse within two years following front line therapy with limited treatment options available[3][4]. Treatment of relapsed and refractory T-ALL remains a high unmet medical need.

Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020

On April 28, 2020 Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, reported that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2020 on Tuesday, May 5, 2020, and to host a conference call the same day at 4:30 p.m. ET (Press release, Synthetic Biologics, APR 28, 2020, View Source [SID1234556718]). The dial-in information for the call is as follows:

U.S. (toll free): 1-888-347-5280
International: +1-412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at View Source." target="_blank" title="View Source." rel="nofollow">View Source An archived replay of the call will be available for approximately ninety (90) days at the same URL, View Source beginning approximately one hour after the call’s conclusion.

Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets

On April 28, 2020 Nektar Therapeutics (Nasdaq: NKTR) reported that it will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets (Press release, Nektar Therapeutics, APR 28, 2020, View Source [SID1234556717]). Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: View Source The web broadcast of the conference call will be available for replay through Monday, June 1, 2020.

To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Conference ID: 8288857 (Nektar Therapeutics is the host)